#United States #New York #Class Action #Levi & Korsinsky #REGENXBIO

REGENXBIO Class Action Notice

Levi & Korsinsky, LLP, a prominent law firm specializing in investor rights, has announced important news for investors in REGENXBIO Inc. (NASDAQ: RGNX). The firm is currently managing a class action lawsuit aimed at compensating investors who suffered losses due to alleged securities fraud. The deadline for affected investors to join this action is set for April 14, 2026.

Case Overview

The class action filed by Levi & Korsinsky seeks to represent individuals who invested in REGENXBIO during the period from February 9, 2022, to January 27, 2026. According to the lawsuit, the company is accused of misleading investors about the safety and effectiveness of its investigational gene therapy product, RGX-111, intended for the treatment of severe Mucopolysaccharidosis Type I, commonly known as Hurler syndrome.

The complaint alleges that while the defendants made overly optimistic statements regarding RGX-111's trial success—based on favorable biomarker data from ongoing clinical studies—they simultaneously concealed critical adverse information. This included troubling data concerning the efficacy of RGX-111, which should have been disclosed to investors.

Significant Developments

On January 28, 2026, just after the end of the class action period, REGENXBIO announced a press release indicating that the FDA had placed a clinical hold on RGX-111 due to the discovery of an intraventricular CNS tumor in a participant of the Phase I/II study. This shocking announcement resulted in a significant decline in REGENXBIO’s stock price, dropping from $13.41 to $11.01—representing a staggering 17.8% decrease in just a single day.

What Affected Investors Should Do

Investors who believe they have incurred financial losses due to the misleading actions of REGENXBIO have until April 14, 2026, to seek inclusion in the class action. The process to join does not require individuals to be lead plaintiff in order to participate in any potential recovery. Levi & Korsinsky emphasizes that there are no fees or costs associated with participation, offering a unique opportunity for investors to seek justice at no financial risk.

You can find more details and apply to join the class action by following this link: Join Class Action Against REGENXBIO. Additionally, interested parties may reach out directly to attorney Joseph E. Levi at (212) 363-7500 or via email at [email protected] for further assistance.

Expertise of Levi & Korsinsky

With over 20 years of experience in securities litigation, Levi & Korsinsky has a track record of recovering hundreds of millions of dollars for shareholders. The firm is noted for its high-stakes cases and ranks among the top securities litigation firms, as recognized by ISS Securities Class Action Services. Their dedicated team, comprising over 70 skilled professionals, is prepared to support investors through this process.

As investors face uncertainty in the wake of disappointing announcements from REGENXBIO, it is essential for those affected to act swiftly to secure their rights and explore potential compensation.

Contact Information
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Email: [email protected]
Website: www.zlk.com

Stay informed and ensure your rights as an investor remain protected.